HBeAg阳性慢性乙型肝炎患者经核苷和核苷酸类药物治疗达标停药后复发的相关因素

胡伯斌; 江建宁; 付嘉鑫; 王保健; 吴晓莉; 梁鹏; 莫燕燕; 傅燕平; 杜漫; 刘宇

doi:10.3969/j.issn.1001-5256.2016.05.014

HBeAg阳性慢性乙型肝炎患者经核苷和核苷酸类药物治疗达标停药后复发的相关因素

DOI: 10.3969/j.issn.1001-5256.2016.05.014

1. 广西医科大学第一附属医院
2. 广西壮族自治区民族医院

基金项目:

广西自然科学基金项目(2014GXNSFDA118023)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 2444
- HTML全文浏览量: 51
- PDF下载量: 459
- 被引次数: 0
出版历程
- 出版日期: 2016-05-20

Risk factors for recurrence after drug withdrawal in HBeAg-positive chronic hepatitis B patients completing pharmacotherapy with nucleos(t) ide analogues

The First Hospital, Guangxi Medical University

Research funding:

摘要

摘要:
目的探讨影响核苷和核苷酸类药物（NAs）治疗HBeAg阳性的慢性乙型肝炎（CHB）患者达到治疗终点停药后复发的相关因素。方法选取2004年5月-2014年12月于广西医科大学第一附属医院就诊并接受NAs治疗的HBeAg阳性CHB患者60例,达到相关指南治疗停药标准后停药。将性别、年龄、HBV感染家族史、基线HBV DNA载量、基线TBil、基线ALT水平、基线AST水平、病毒学应答时间、HBeAg消失时间、开始用药至发生HBeAg血清学转换时间、HBeAg血清学转换后巩固治疗时间、总疗程、延长疗程、停药时HBsAg水平、药物种类共15个可能影响复发的因素进行单因素、多因素Cox比例风险回归模型分析,累积复发率采用Kaplan-Meier法进行分析。结果 60例患者平均疗程（37.36±12.67）个月,延长疗程7.0（2.013.0）个月,48个月的复发率为56.7%。性别、年龄、基线HBV DNA载量、基线TBil、基线ALT水平、基线AST水平、病毒学应答时间、巩固治疗时间、总疗程、延长疗程、药物种类对达标停药后复发无明显影响（P值均>0.05）。多因素...
- 肝炎,乙型,慢性 /
- 肝炎e抗原,乙型 /
- 抗病毒药 /
- 复发
Abstract:
Objective To investigate the risk factors for recurrence after drug withdrawal in HBeAg- positive chronic hepatitis B( CHB)patients completing the treatment with nucleos( t) ide analogues( NAs). Methods A total of 60 HBeAg- positive CHB patients who visited and were treated in The First Hospital Affiliated to Guangxi Medical University from May 2004 to December 2014 were enrolled. The drugs were withdrawn after the patients reached the criteria for drug withdrawal in related guidelines. The univariate and multivariate Cox proportional hazards regression model analyses were performed for 15 factors which might influence recurrence,i. e.,sex,age,a family history of HBV infection,baseline HBV DNA load,baseline total bilirubin( TBil) level,baseline alanine aminotransferase( ALT) level,baseline aspartate aminotransferase( AST) level,duration of virologic response,time to disappearance of HBeAg,time from the start of medication to the development of HBeAg seroconversion,duration of consolidation therapy after HBeAg seroconversion,total course of the treatment,prolonged course of the treatment,HBs Ag level at drug withdrawal,and drug type. The Kaplan- Meier method was used for calculating the cumulative recurrence rate. Results The mean course of the treatment was 37. 36 ± 12. 67 months,the prolonged course of the treatment was 7. 0( 2. 0 ~ 13. 0) months,and 56. 7% of all patients experienced recurrence. Sex,age,baseline HBV DNA load,baseline TBil level,baseline ALT level,baseline AST level,duration of virologic response,duration of consolidation therapy,total course of the treatment,prolonged course of the treatment,and drug type were not significantly associated with recurrence after drug withdrawal in patients who met the criteria for drug withdrawal( all P > 0. 05). A family history of HBV infection( RR = 1. 583,P = 0. 047),time to HBeAg seroconversion( RR = 1. 205,P = 0. 015),and HBs Ag level at drug withdrawal were independent risk factors for recurrence after drug withdrawal. The patients with time to HBeAg seroconversion > 12 months had a significantly higher recurrence rate than those with time to HBeAg seroconversion < 12 months( 80. 0% vs 48. 9%,P < 0. 001). Conclusion A family history of HBV infection,delayed HBeAg seroconversion,and high HBs Ag level at drug withdrawal are major risk factors for recurrence after drug withdrawal in HBeAg- positive CHB patients who have met the criteria for drug withdrawal in the treatment with NAs. If HBeAg- positive CHB patients can acquire immune control,recurrence after withdrawal of NAs will be reduced.
- hepatitis B,chronic /
- hepatitis B e antigens /
- antiviral agents /
- recurrence

HTML全文

参考文献(16)

[1]Experts Attending the Discussion on Long-Treatment of Chronic Hepatitis B.Long-term treatment of chronic hepatitis B[J].J Clin Hepatol,2014,30(11):1099-1105.(in Chinese)慢性乙型肝炎长期治疗讨论会专家.核苷和核苷酸类药物治疗慢性乙型肝炎的长期性[J].临床肝胆病杂志,2014,30(11):1099-1105.

[2]Working Group on Consensus Statements on Treatment of Chronic Hepatitis B,Asian Pacific Association for the Study of the Liver.Asian-pacific consensus statement on the management of chronic hepatitis B:a 2012 update[J].J Clin Hepatol,2012,28(8):6-21.(in Chinese)亚太肝病学会慢性乙型肝炎治疗共识工作组.亚太地区慢性乙型肝炎治疗共识(2012最新版)[J].临床肝胆病杂志,2012,28(8):6-21.

[3]Chinese Society of Infectious Diseases and Parasitology,Chinese Society of Hepatology,Chinese Medical Association.Prevention and treatment of viral hepatitis[J].Chin J Infect Dis,2001,19(1):56-62.(in Chinese)中华医学会传染病与寄生虫病学分会、肝病学分会.病毒性肝炎防治方案[J].中华传染病杂志,2001,19(1):56-62.

[4] Chinese Society of Hepatology,Chinese Medical Association,Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Chin Hepatol,2011,27(1):Ⅰ-ⅩⅥ.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].临床肝胆病杂志,2011,27(1):Ⅰ-ⅩⅥ.

[5]CHI H,HANSEN BE,YIM C,et al.Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B[J].Aliment Pharmacol Ther,2015,41(9):867-876.

[6]European Association for the Study of the Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.

[7]LOK AS,McM AHON BJ.Chronic hepatitis B:update 2009[J].Hepatology,2009,5(3):661-662.

[8]ZHOU YL,WANG XC,WU YT,et al.Association between HBeA g seroconversion and HBV specific cellular immunity in patients with chronic hepatitis B treated with adefovir dipivoxil[J/CD].Chin J Clinicians:Electronic Edition,2012,6(24):8337-8339.(in Chinese)周玉麟,王学才,吴寅涛,等.阿德福韦酯治疗慢性乙型肝炎HBeA g血清学转换与HBV特异性细胞免疫的关系[J/CD].中华临床医师杂志:电子版,2012,6(24):8337-8339.

[9]CHEN XY,CAO ZH.Designing efficacious treatment strategies to achieve sustained immunological control of hepatitis infection in HBeA g-positive patients[J].Chin J Hepatol,2013,21(7):484-487.(in Chinese)陈新月,曹振环.提高HBeA g阳性慢性乙型肝炎患者持久免疫控制的治疗策略[J].中华肝脏病杂志,2013,21(7):484-487.

[10]KONDO Y,UENO Y,SHIMOSEGAWA T,et al.Immunopathogenesis of hepatitis B persistent infection:implications for immunotherapeutic strategies[J].Clin J Gastroenterol,2009,2(2):71-79.

[11] XIE QX,JIANG XP,ZHANG YF,et al.Intrahepatic hepatitis B virus covalently closed circular DNA correlation with serum HBV DNA,serum HBsA g,alanine aminotransferase and age[J].Chin J Hepatol,2015,23(6):418-421.(in Chinese)谢琴秀,江晓平,张亚飞,等.HBV共价闭合环状DNA与血清HBV DNA、HBsA g、ALT、年龄的相关性研究[J].中华肝脏病杂志,2015,23(6):418-421.

[12]GU SW.Study on the familial aggregation of 652 cases of hepatitis B[J].Chin Hepatol,2009,14(2):103-104.(in Chinese)顾生旺.652例乙型肝炎患者家族聚集性研究[J].肝脏,2009,14(2):103-104.

[13]BUSCA A,KUMAR A.Innate immune responses in hepatitis B virus(HBV)infection[J].Virol J,2013,11(2):1-8.

[14] BERTOLETTI A,FERRARI C.Innate and adaptive immune responses in chronic hepatitis B virus infections:towards restoration of immune control of viral infection[J].Gut,2012,61(12):1754-1764.

[15] CHI H,HANSEN BE,YIM C,et al.Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B[J].Aliment Pharmacol Ther,2015,41(9):867-876.

[16]Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.

施引文献

资源附件(0)

访问统计